United Therapeutics CORP Form 4 insider transactions
NASDAQ
Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on March 13 and 14, 2024, under a pre-arranged 10b5-1 trading plan.
NASDAQ
Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on March 11 and 12, 2024, under a pre-arranged 10b5-1 trading plan.
NASDAQ
Director Judy D. Olian exercised stock options and sold shares of United Therapeutics Corp (UTHR) on March 12, 2024.
NASDAQ
Form 4: United Therapeutics Director Tommy G Thompson Executes Share Tracking Award and Sells Shares
Director Tommy G Thompson exercised share tracking awards and sold shares of United Therapeutics Corp on March 11, 2024.
NASDAQ
Katherine J. Klein, a director at United Therapeutics Corp, reported the exercise of share tracking awards and subsequent disposal of common stock on March 8, 2024.
NASDAQ
Martine Rothblatt, CEO of United Therapeutics, executed stock option exercises and sales on March 7th and 8th, 2024, under a pre-arranged 10b5-1 trading plan.
NASDAQ
Director Tommy G Thompson reports the acquisition and disposal of United Therapeutics Corp stock and share tracking awards on March 8, 2024.
NASDAQ
Form 4: United Therapeutics EVP Paul Mahon Executes Stock Options and Sells Shares Under 10b5-1 Plan
Paul Mahon, EVP & General Counsel of United Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.
NASDAQ
Form 4: United Therapeutics Director Richard Giltner Executes Share Tracking Award, Disposes of Shares
Director Richard Giltner executed a share tracking award and disposed of 10,000 shares of United Therapeutics Corp stock on March 6, 2024.
NASDAQ
Director Tommy G. Thompson reports acquisition and disposal of United Therapeutics Corp shares, including transactions involving share tracking awards.
NASDAQ
Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales of common stock on March 5th and 6th, 2024, under a pre-arranged 10b5-1 trading plan.
NASDAQ
Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.
NASDAQ
Form 4: United Therapeutics Director Tommy G. Thompson Executes Share Tracking Award, Adjusts Holdings
Director Tommy G. Thompson exercised share tracking awards and adjusted his holdings in United Therapeutics Corp. on March 1, 2024.